Medium to long-term clinical outcomes with everolimus-eluting stents in real-life percutaneous coronary intervention.
- Author:
Michael LIANG
1
;
The Vun LIEW
;
Aniket PURI
;
Lauren HYDE
;
Gerard DEVLIN
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; methods; Aspirin; therapeutic use; Coronary Artery Disease; drug therapy; mortality; therapy; Drug-Eluting Stents; Everolimus; Female; Humans; Immunosuppressive Agents; administration & dosage; therapeutic use; Male; Middle Aged; New Zealand; Platelet Aggregation Inhibitors; therapeutic use; Registries; Retrospective Studies; Sirolimus; administration & dosage; analogs & derivatives; therapeutic use; Survival Analysis; Ticlopidine; analogs & derivatives; therapeutic use; Time Factors; Treatment Outcome
- From:Annals of the Academy of Medicine, Singapore 2012;41(6):252-257
- CountrySingapore
- Language:English
-
Abstract:
INTRODUCTIONEverolimus eluting stents (EES) have demonstrated excellent re-stenosis and thrombosis rates in a number of randomised controlled trials. This study reported the real world experience in a single tertiary centre with EES in predominantly acute coronary syndrome (ACS) patients and compared the outcomes in small and large vessels. We measured the medium to long-term major adverse cardiovascular events (MACE) defined as all-cause mortality, myocardial infarction (MI) and target vessel revascularisation (TVR) and stent thrombosis.
MATERIALS AND METHODSAll consecutive patients underwent percutaneous coronary intervention (PCI) with EES (PROMUSTM, Boston Scientific, Natick USA; XIENCE VTM, Abbott Vascular, Santa Clara USA) between March 2007 and September 2009 recorded in our coronary intervention registry were included in this study. All patients were advised to stay on dual antiplatelet therapy with Aspirin 100 mg/day and Clopidogrel 75 mg/day. All patients had at least 6 months of clopidogrel, government funded and a further 6 months required self funding.
RESULTSFour hundred and six consecutive patients received EES during the study period; 403 were included in this study and 3 were lost to follow-up. Indications for PCI were stable angina in 11% of the patients, unstable angina in 38%, non-ST elevation myocardial infarction in 43%, and ST-elevation myocardial infarction in 8%. Procedural success was achieved in 99.5% of the cases. During a median follow-up of 23 months, 3% of the patients had an MI, 3% underwent TVR, 5% all-cause mortality and 2 (0.5%) cases of definite or probable stent thrombosis. The Kaplan Meier 2-year survival and MACE free survival were 95% and 89% respectively. A subgroup analysis comparing MACE in patients who were treated with a single small (≤ 2.75 mm; n = 91) or large (≥ 3 mm; n = 118). EES did not show significant difference during the 2-year follow-up (12% vs 9%; P = 0.34).
CONCLUSIONEverolimus eluting stent appears to be safe in a real world setting with satisfactory median-term outcomes which include low rates of TVR and other adverse events. EES appear to be equally effective in both small and large vessels.
